Influenza A virus H1N1 vaccine (CSL 425) - CSL Biotherapies

Drug Profile

Influenza A virus H1N1 vaccine (CSL 425) - CSL Biotherapies

Alternative Names: CSL 425; CSL monovalent H1N1 influenza virus vaccine (CSL425); Inactivated H1N1 vaccine (unadjuvanted) - CSL; Influenza A/H1N1 2009 vaccine; Panvax H1N1; Swine flu vaccine - CSL

Latest Information Update: 04 Jun 2010

Price : $50

At a glance

  • Originator CSL
  • Class Antivirals; Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 22 May 2010 CSL completes the phase II CSLCT-CAL-09-60 trial in the prevention of Influenza-A virus H1N1 subtype infections in healthy children in USA
  • 22 May 2010 CSL completes the phase II CSLCT-CAL-09-59 trial in the prevention of Influenza-A virus H1N1 subtype infections in healthy adults in Australia
  • 22 Dec 2009 Efficacy and adverse events data from a phase II trial in Influenza-A virus H1N1 subtype released by CSL
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top